ZymoGenetics plans to sell a parcel of vacant land near its Seattle headquarters.
ZymoGenetics wants to turn some of its land into cash before the end of the year.
The Seattle biotechnology company said in a regulatory filing that it wants to sell a vacant lot near its Eastlake headquarters.
The traransaction is “still in negotiation, not settled,” said spokeswoman Susan Specht on Wednesday, but a sale would “a nice chunk of change.”
The land, previously tagged for future expansion, has a carrying cost of $4.5 million, according to a filing with the Securities and Exchange Commission.
Most Read Business Stories
- Seattle artists worry potential sale of historic INS building could spell the end for their studios
- Frontier cancels flight, citing maskless passengers
- Fired after organizing, Starbucks baristas turned down a payout and took their bosses to court
- 6 Dr. Seuss books won't be published for racist images
- The penthouse atop Smith Tower is on the rental market for the first time
It’s not the first time that ZymoGenetics sheds real estate. In 2002, the company sold its state-of-the-art headquarters for $52 million, and it now leases the building, a historic power plant near Lake Union.
“We’re not in the real estate business,” said Specht. Selling the lot is a way to “monetize our assets in the best interest of shareholders.”
Ángel González: 206-515-5644 or email@example.com